Stereotactic Radiation Therapy for Benign Meningioma: Long-Term Outcome in 318 Patients

2014 ◽  
Vol 89 (3) ◽  
pp. 569-575 ◽  
Author(s):  
Emmanouil Fokas ◽  
Martin Henzel ◽  
Gunar Surber ◽  
Klaus Hamm ◽  
Rita Engenhart-Cabillic
Keyword(s):  
Radiation Therapy ◽  
Stereotactic Radiation Therapy ◽  
Benign Meningioma ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Stereotactic Radiation

Long-term outcome of patients with hepatocellular carcinoma treated with hypofractionated stereotactic radiation therapy as a bridge to liver transplantation.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 368-368
Author(s):  
Alan W. Katz ◽  
Douglas P Rosenzweig
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Complete Response ◽  
Pathological Examination ◽  
Invasive Treatment ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Stereotactic Radiation ◽  
Bridge Therapy

368 Background: Stereotactic hypofractionated radiation therapy (SHORT) is a safe, non-invasive, treatment modality for patients with hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the long-term outcome of patients with HCC receiving SHORT as a bridge therapy to LT. Methods: We reviewed 9 consecutive patients who underwent LT between 2008 and 2010 after receiving SHORT as bridge therapy. Radiation therapy was delivered using a 6 MV linear accelerator and an infrared based patient posititiong system. Total dose was 50 Gy in 10 fractions. Doses were prescribed to the 100% isodose line (IDL), with the 80% IDL covering the gross tumor plus a minimum margin of 7 mm. Survival was measured from the date of LT. Results: Median time from completion of SHORT to LT was 5.9 months (range; 0.9-15.7 months). After a median follow up of 48.6 months (range; 17.8-65.3 months) all patients were still alive. No significant surgical complications were seen in any of the patients. 8 patients demonstrated necrosis in the treated tumors, ranging from 8-100%. Only 1 patient did not show any treatment effect on pathological examination. One patient developed recurrent disease in a lymph node and in the transplanted liver, both treated by SHORT with complete response. Conclusions: SHORT is a safe and effective bridging therapy with patients experiencing excellent disease-free and overall survival following LT.

Long-Term Outcomes for Nonacoustic Schwannomas Treated with Stereotactic Radiation Therapy

2019 ◽  
Author(s):  
Anna Bistline ◽  
Andrew Song ◽  
James Evans ◽  
Christopher Farrell ◽  
David Andrews ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Stereotactic Radiation Therapy ◽  
Long Term Outcomes ◽  
Stereotactic Radiation

Long-term outcomes in children with glioblastoma

2010 ◽  
Vol 6 (2) ◽  
pp. 145-149 ◽  
Author(s):  
Kyung Sun Song ◽  
Ji Hoon Phi ◽  
Byung-Kyu Cho ◽  
Kyu-Chang Wang ◽  
Ji Yeoun Lee ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Progression Free Survival ◽  
Radical Resection ◽  
Tumor Location ◽  
Recurrent Glioblastoma ◽  
Subtotal Resection ◽  
Long Term Outcomes ◽  
Term Outcome ◽  
Long Term Outcome

Object Glioblastoma is the most common primary malignant brain tumor; however, glioblastoma in children is less common than in adults, and little is known about its clinical outcome in children. The authors evaluated the long-term outcome of glioblastoma in children. Methods Twenty-seven children were confirmed to have harbored a glioblastoma between 1985 and 2007. The clinical features and treatment outcomes were reviewed retrospectively. All patients underwent resection; complete resection was performed in 12 patients (44%), subtotal resection in 12 patients (44%), and biopsy in 3 patients (11%). Twenty-four patients (89%) had radiation therapy, and 14 (52%) patients received chemotherapy plus radiation therapy. Among the latter, 5 patients had radiation therapy concurrent with temozolomide chemotherapy. Four patients with small-size recurrent glioblastoma received stereotactic radiosurgery. Results The median overall survival (OS) was 43 months, and the median progression-free survival was 12 months. The OS rate was 67% at 1 year, 52% at 2 years, and 40% at 5 years. The median OS was significantly associated with tumor location (52 months for superficially located tumors vs 7 months for deeply located tumors; p = 0.017) and extent of removal (106 months for completely resected tumors vs 11 months for incompletely resected tumors; p < 0.0001). Conclusions The prognosis of glioblastoma is better in children than in adults. Radical resection followed by concurrent chemoradiation therapy may be the initial treatment of choice.

Recurrent pleomorphic adenoma of the parotid gland: Long-term outcome of patients treated with radiation therapy

2006 ◽  
Vol 66 (4) ◽  
pp. 1031-1035 ◽  
Author(s):  
Allen M. Chen ◽  
Joaquin Garcia ◽  
M. Kara Bucci ◽  
Jeanne M. Quivey ◽  
David W. Eisele
Keyword(s):  
Radiation Therapy ◽  
Parotid Gland ◽  
Pleomorphic Adenoma ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Recurrent Pleomorphic Adenoma

Long-term outcome in patients with central neurocytoma following stereotactic biopsy and radiation therapy

2002 ◽  
Vol 16 (2) ◽  
pp. 126-132 ◽  
Author(s):  
V. Kulkarni ◽  
V. Rajshekhar ◽  
R. P. Haran ◽  
S. M. Chandi
Keyword(s):  
Radiation Therapy ◽  
Stereotactic Biopsy ◽  
Central Neurocytoma ◽  
Term Outcome ◽  
Long Term Outcome
Sign in / Sign up

Export Citation Format

Share Document